ADAMTS13 and Thrombocytopenia: The thrombocytopenia decreased shortly after the discontinuation of caplacizumab, combined with an ADAMTS13 inhibitor titer of 3.5 BU/mL and ADAMTS13 activity of 18%, which indicated insufficient recovery; diagnosis of relapse was made.